← Leaderboards
Thomas William Geisbert
Boston University Medical Campus
$89,759,942
Attributed
$94,220,109
Total exposure
25
Grants
23
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $62.3M · FY2009–25$100M$75M$50M$25M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$202,757,088 · 28
By mechanism
U19$170,871,408 · 18
R01$22,086,809 · 5
U01$7,721,472 · 2
R44$1,293,392 · 1
U54$718,248 · 1
P51$65,759 · 1
Top collaborators
- John H Eldridge5 shared
- Ian Maclachlan4 shared
- M. Javad Aman2 shared
- Christopher Broder1 shared
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Rachel Fearns$7,047,659
- Elke C Muhlberger$21,534,041
- Katharine Nina Bossart$277,770
- Elizabeth Yvonne Flores$48,974
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesVirusNonhuman PrimateVirus DiseasesEbola VirusDisease OutbreaksAnimalsBaseCase Fatality RatesNational Institute Of Allergy And Infectious DiseasePathogenFilovirusProgramsResearch PersonnelRecombinantsInfectionLaboratoriesMedicalResearch Project GrantsIn VitroDesignCategoriesReportingMonoclonal Antibodies
Grant awards (90)
Preclinical development of a vaccine for Nipah virus$1,157,701
R01 · FY2025 · AI · contact PI
Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease$1,000,000
R44 · FY2025 · AI
Paramyxoviridae and Bunyavirales Vaccines and Antibodies Center (PABVAX)$46,404,982
U19 · FY2024 · AI · contact PI
Core D: Animal models and vaccine evaluation$5,867,641
U19 · FY2024 · AI · contact PI
Core A: Administrative Core$4,640,499
U19 · FY2024 · AI · contact PI
Core E: Animal Model Development and Preclinical Evaluation$4,640,498
U19 · FY2024 · AI · contact PI
Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine$740,024
R01 · FY2024 · AI · contact PI
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections$7,043,167
U19 · FY2023 · AI · contact PI
BSL-4 Evaluation Core (Core B)$2,890,889
U19 · FY2023 · AI · contact PI
Core C - The University of Texas Medical Branch at Galveston$2,538,747
U19 · FY2023 · AI · contact PI
Discovery of novel Henipavirus inhibitors$2,317,735
U19 · FY2023 · AI · contact PI
Preclinical development of a vaccine for Nipah virus$1,159,045
R01 · FY2023 · AI · contact PI
Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine$739,915
R01 · FY2023 · AI · contact PI
Research Project 3: siRNA Therapy and Small Molecule Combination Treatment for Filoviruses$723,636
U19 · FY2023 · AI · contact PI
Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease$293,392
R44 · FY2023 · AI
Administrative Core (Core A)$202,536
U19 · FY2023 · AI · contact PI
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections$7,043,167
U19 · FY2022 · AI · contact PI
Discovery of novel Henipavirus inhibitors$5,291,771
U19 · FY2022 · AI · contact PI
BSL-4 Evaluation Core (Core B)$2,834,158
U19 · FY2022 · AI · contact PI
Preclinical development of a vaccine for Nipah virus$1,179,782
R01 · FY2022 · AI · contact PI
Core C - The University of Texas Medical Branch at Galveston$802,301
U19 · FY2022 · AI · contact PI
Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine$740,027
R01 · FY2022 · AI · contact PI
Research Project 3: siRNA Therapy and Small Molecule Combination Treatment for Filoviruses$663,941
U19 · FY2022 · AI · contact PI
Administrative Core (Core A)$206,199
U19 · FY2022 · AI · contact PI
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections$7,043,167
U19 · FY2021 · AI · contact PI
BSL-4 Evaluation Core (Core B)$2,542,134
U19 · FY2021 · AI · contact PI
Preclinical development of a vaccine for Nipah virus$1,415,990
R01 · FY2021 · AI · contact PI
Core C - The University of Texas Medical Branch at Galveston$1,144,444
U19 · FY2021 · AI · contact PI
Preclinical Development of Human Monoclonal Antibodies for Postexposure Treatment of Crimean-Congo Hemorrhagic Fever$1,104,705
R01 · FY2021 · AI · contact PI
Research Project 3: siRNA Therapy and Small Molecule Combination Treatment for Filoviruses$770,799
U19 · FY2021 · AI · contact PI
Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine$642,313
R01 · FY2021 · AI · contact PI
Administrative Core (Core A)$188,571
U19 · FY2021 · AI · contact PI
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections$7,339,433
U19 · FY2020 · AI · contact PI
BSL-4 Evaluation Core (Core B)$2,655,768
U19 · FY2020 · AI · contact PI
Preclinical Development of Human Monoclonal Antibodies for Postexposure Treatment of Crimean-Congo Hemorrhagic Fever$1,117,358
R01 · FY2020 · AI · contact PI
Core C - The University of Texas Medical Branch at Galveston$852,988
U19 · FY2020 · AI · contact PI
Research Project 3: siRNA Therapy and Small Molecule Combination Treatment for Filoviruses$714,651
U19 · FY2020 · AI · contact PI
Preclinical Development of a Crimean-Congo Hemorrhagic Fever Virus Vaccine$670,889
R01 · FY2020 · AI · contact PI
Administrative Core (Core A)$205,183
U19 · FY2020 · AI · contact PI
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections$7,043,167
U19 · FY2019 · AI · contact PI
BSL-4 Evaluation Core (Core B)$2,665,747
U19 · FY2019 · AI · contact PI
Preclinical Development of Human Monoclonal Antibodies for Postexposure Treatment of Crimean-Congo Hemorrhagic Fever$1,210,843
R01 · FY2019 · AI · contact PI
Core C - The University of Texas Medical Branch at Galveston$780,615
U19 · FY2019 · AI · contact PI
Research Project 3: siRNA Therapy and Small Molecule Combination Treatment for Filoviruses$692,621
U19 · FY2019 · AI · contact PI
Administrative Core (Core A)$205,732
U19 · FY2019 · AI · contact PI
Advancement of Treatments for Ebola and Marburg Virus Infections$4,496,579
U19 · FY2018 · AI · contact PI
BSL4 Evaluation Core$2,566,443
U19 · FY2018 · AI · contact PI
Preclinical Development of Human Monoclonal Antibodies for Postexposure Treatment of Crimean-Congo Hemorrhagic Fever$1,235,927
R01 · FY2018 · AI · contact PI
Modulation of innate and adaptive immunity of filoviruses in macaques$733,346
U19 · FY2018 · AI · contact PI
Administrative Core$220,737
U19 · FY2018 · AI · contact PI
Advancement of Treatments for Ebola and Marburg Virus Infections$5,172,726
U19 · FY2017 · AI · contact PI
BSL4 Evaluation Core$3,057,440
U19 · FY2017 · AI · contact PI
Preclinical Development of Human Monoclonal Antibodies for Postexposure Treatment of Crimean-Congo Hemorrhagic Fever$1,345,347
R01 · FY2017 · AI · contact PI
Modulation of innate and adaptive immunity of filoviruses in macaques$743,530
U19 · FY2017 · AI · contact PI
Supplemental Research Project (SRP)$243,980
U19 · FY2017 · AI · contact PI
Administrative Core$232,944
U19 · FY2017 · AI · contact PI
Advancement of Treatments for Ebola and Marburg Virus Infections$5,485,257
U19 · FY2016 · AI · contact PI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses$1,208,817
R01 · FY2016 · AI
BSL4 Evaluation Core$1,197,196
U19 · FY2016 · AI · contact PI
Modulation of innate and adaptive immunity of filoviruses in macaques$778,455
U19 · FY2016 · AI · contact PI
Modulation of innate and adaptive immunity of filoviruses in macaques$777,615
U19 · FY2016 · AI · contact PI
Administrative Core$204,862
U19 · FY2016 · AI · contact PI
Advancement of Treatments for Ebola and Marburg Virus Infections$5,777,478
U19 · FY2015 · AI · contact PI
BSL4 Evaluation Core$1,755,449
U19 · FY2015 · AI · contact PI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses$947,203
R01 · FY2015 · AI
Modulation of innate and adaptive immunity of filoviruses in macaques$784,263
U19 · FY2015 · AI · contact PI
Administrative Core$213,726
U19 · FY2015 · AI · contact PI
Advancement of Treatments for Ebola and Marburg Virus Infections$5,687,856
U19 · FY2014 · AI · contact PI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses$937,397
R01 · FY2014 · AI
BSL4 Evaluation Core$829,380
U19 · FY2014 · AI · contact PI
Modulation of innate and adaptive immunity of filoviruses in macaques$799,758
U19 · FY2014 · AI · contact PI
Administrative Core$155,501
U19 · FY2014 · AI · contact PI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses$1,122,164
R01 · FY2013 · AI
Nipah & Hendra Virus Nonhuman Primate Model & Therapeutics Development$967,287
U01 · FY2013 · AI · contact PI
RNA Interference for the Treatment of Ebola and Marburg Hemorrhagic Fever$536,968
R01 · FY2013 · AI · contact PI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses$1,120,171
R01 · FY2012 · AI
Nipah & Hendra Virus Nonhuman Primate Model & Therapeutics Development$1,101,571
U01 · FY2012 · AI · contact PI
RNA Interference for the Treatment of Ebola and Marburg Hemorrhagic Fever$571,407
R01 · FY2012 · AI · contact PI
Nipah & Hendra Virus Nonhuman Primate Model & Therapeutics Development$1,160,710
U01 · FY2011 · AI · contact PI
RNA Interference for the Treatment of Ebola and Marburg Hemorrhagic Fever$585,129
R01 · FY2011 · AI · contact PI
Treatments for Nipah Virus Infection$239,872
U54 · FY2011 · AI · contact PI
Nipah & Hendra Virus Nonhuman Primate Model & Therapeutics Development$982,178
U01 · FY2010 · AI · contact PI
Multivalent Vaccine for Viral Hemorrhagic Fever$908,442
U01 · FY2010 · AI · contact PI
RNA Interference for the Treatment of Ebola and Marburg Hemorrhagic Fever$597,687
R01 · FY2010 · AI · contact PI
Nipah & Hendra Virus Nonhuman Primate Model & Therapeutics Development$338,312
U01 · FY2010 · AI · contact PI
Treatments for Nipah Virus Infection$252,743
U54 · FY2010 · AI · contact PI
VACCINE NEUROVIRULENCE STUDY IN MONKEYS (VSV FILOVIRUS VACCINE)$65,759
P51 · FY2010 · RR · contact PI
Nipah & Hendra Virus Nonhuman Primate Model & Therapeutics Development$1,316,712
U01 · FY2009 · AI · contact PI
Multivalent Vaccine for Viral Hemorrhagic Fever$946,260
U01 · FY2009 · AI · contact PI
Treatments for Nipah Virus Infection$225,633
U54 · FY2009 · AI · contact PI